TY - JOUR
T1 - The cost and impact of compulsivity
T2 - A research perspective
AU - Hollander, Eric
AU - Doernberg, Ellen
AU - Shavitt, Roseli
AU - Waterman, Richard J.
AU - Soreni, Noam
AU - Veltman, Dick J.
AU - Sahakian, Barbara J.
AU - Fineberg, Naomi A.
N1 - Funding Information:
Eric Hollander has the following disclosures: for consultancy, Roche, Coronado, and Transcept; for research support, Roche, Sunovion, Lundbeck, Forest, Coronado, and Brainsway. Roseli Shavitt has the following disclosures for the last few years: travel grants from Lundbeck to attend the European College of Neuropsychopharmacology Meeting in Barcelona, 2013, and Vienna, 2012, and lectures for Abbott in 2014. Barbara J Sahakian consults for Cambridge Cognition, Otsuka, Servier, and Lundbeck. She holds a grant funded by Janssen/J&J. In the past several years, Naomi A. Fineberg has received research support from Lundbeck, Glaxo-SmithKline, European College of Neuropsychopharmacology (ECNP), Servier, Cephalon, Astra Zeneca, Medical Research Council (UK), National Institute for Health Research, Wellcome Foundation. Dr. Fineberg has received honoraria for lectures at scientific meetings from Lundbeck, Servier, Astra Zeneca, Jazz pharmaceuticals, Bristol Myers Squibb, UK College of Mental Health Pharmacists, British Association for Psychopharmacology (BAP). Dr. Fineberg has received financial support to attend scientific meetings from Janssen, Lundbeck, Servier, Novartis, Bristol Myers Squibb, Cephalon, International College of Obsessive-Compulsive Spectrum Disorders, International Society for Behavioural Addiction, ECNP, BAP, World Health Organization, Royal College of Psychiatrists. Dr. Fineberg has received financial royalties for publications from Oxford University Press and Taylor and Francis. Ellen Doernberg, Richard Waterman, Noam Soreni, and Dick J. Veltman have nothing to disclose.
Publisher Copyright:
© 2016 Elsevier B.V. and ECNP.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Compulsivity is the defining feature of various psychiatric disorders including Obsessive Compulsive Related Disorders (OCRDs), and other compulsive, impulsive, and addictive disorders. These disorders are disabling, chronic conditions with an early onset and high rates of comorbidity, misdiagnoses, and delay in treatment onset. Disorders of compulsivity are responsible for considerable socioeconomic burden to society. We review the costs and impacts of compulsivity. In order to facilitate earlier diagnosis and targeted treatments, we examine the overlapping mechanisms that underlie compulsivity. We reconceptualize psychiatric disorders based on core features of compulsivity, highlight challenges in harmonizing research in children and adults, describe newer research methodologies, and point to future directions that can impact the costs and impact of disorders of compulsivity.
AB - Compulsivity is the defining feature of various psychiatric disorders including Obsessive Compulsive Related Disorders (OCRDs), and other compulsive, impulsive, and addictive disorders. These disorders are disabling, chronic conditions with an early onset and high rates of comorbidity, misdiagnoses, and delay in treatment onset. Disorders of compulsivity are responsible for considerable socioeconomic burden to society. We review the costs and impacts of compulsivity. In order to facilitate earlier diagnosis and targeted treatments, we examine the overlapping mechanisms that underlie compulsivity. We reconceptualize psychiatric disorders based on core features of compulsivity, highlight challenges in harmonizing research in children and adults, describe newer research methodologies, and point to future directions that can impact the costs and impact of disorders of compulsivity.
KW - Compulsivity
KW - Cost
KW - Diagnosis
KW - OCD
KW - OCRDs
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84969724096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969724096&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2016.02.006
DO - 10.1016/j.euroneuro.2016.02.006
M3 - Article
C2 - 27235690
AN - SCOPUS:84969724096
VL - 26
SP - 800
EP - 809
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
IS - 5
ER -
